Jump to content

TFMFly: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
BogBot (talk | contribs)
Bots
53,132 edits
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
Flaming (talk | contribs)
3,466 edits
adding AFD
Line 1: Line 1:
<!-- Please do not remove or change this AfD message until the issue is settled -->
{{Drugbox
{{Article for deletion/dated|page=2C-TFM|timestamp=20120311070343|year=2012|month=March|day=11|substed=yes}}
<!-- For administrator use only: {{Old AfD multi|page=2C-TFM|date=11 March 2012|result='''keep'''}} -->
<!-- End of AfD message, feel free to edit beyond this point -->{{Drugbox
| verifiedrevid = 385758973
| verifiedrevid = 385758973
| IUPAC_name = (2R)-1-(8-trifluoromethyl-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b’]difuran-4-yl)-2-aminoethane
| IUPAC_name = (2R)-1-(8-trifluoromethyl-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b’]difuran-4-yl)-2-aminoethane

Revision as of 07:03, 11 March 2012

TFMFly
Identifiers
  • (2R)-1-(8-trifluoromethyl-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b’]difuran-4-yl)-2-aminoethane
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H16F3NO2
Molar mass287.277 g/mol g·mol−1
3D model (JSmol)
  • c13OCCc3c(C(F)(F)F)c2OCCc2c1CC(C)N
  (verify)

TFMFly is a compound related to phenethylamine hallucinogens such as 2C-B-FLY and 2C-TFM. It was first reported in 2005 by a team at Purdue University led by David Nichols.[1] It acts as a potent agonist at the 5HT2A serotonin receptor subtype, and is a chiral compound with the more active (R) enantiomer having a Ki of 0.12nM at the human 5HT2A receptor.[2] While the fully aromatic benzodifurans such as bromodragonfly generally have higher binding affinity than saturated compounds like 2C-B-FLY,[3] the saturated compounds have higher efficacy as agonists.[4]


References

  1. ^ Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.
  2. ^ Parrish JC; Braden MR; Gundy E; Nichols DE (2005). "Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists". Journal of Neurochemistry. 95 (6): 1575–84. doi:10.1111/j.1471-4159.2005.03477.x. PMID 16277614. {{cite journal}}: Cite has empty unknown parameter: |author-name-separator= (help); Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  3. ^ Chambers JJ; Kurrasch-Orbaugh DM; Parker MA; Nichols DE (2001). "Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists". Journal of Medicinal Chemistry. 44 (6): 1003–10. doi:10.1021/jm000491y. PMID 11300881. {{cite journal}}: Cite has empty unknown parameter: |author-name-separator= (help); Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  4. ^ Ralf Heim PhD. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. (German)


Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=TFMFly&oldid=481287902"